General Principles - The rules are established to protect shareholders' rights and ensure the orderly conduct and efficiency of shareholder meetings [1] - The shareholder meeting is the company's decision-making body, composed of all shareholders [1][2] - The company must convene shareholder meetings in accordance with laws, regulations, and its articles of association [1][2] Types of Meetings - There are annual and temporary shareholder meetings; the annual meeting must be held within six months after the end of the previous fiscal year [2] - Temporary meetings must be held within two months under certain conditions, such as insufficient directors or significant losses [2][3] Meeting Convening - The board of directors is responsible for convening meetings within the specified time frame [3][4] - Independent directors and the audit committee can propose temporary meetings, requiring majority consent from independent directors [3][4] Proposals and Notifications - Shareholders holding more than 10% of shares can request a temporary meeting, and the board must respond within ten days [4][5] - Proposals for meetings must be submitted in writing and should align with the company's articles of association [6][16] Meeting Procedures - Shareholder meetings must be held at designated locations, and changes require prior notice [28] - The company must provide necessary facilities for shareholders to participate, including online voting options [29][30] Voting and Resolutions - Resolutions can be ordinary or special; ordinary resolutions require a simple majority, while special resolutions require a two-thirds majority [56][58] - Voting rights are based on the number of shares held, with each share granting one vote [59] Record Keeping - Meeting minutes must be recorded, detailing the time, location, attendees, and voting results [53][54] - The company must ensure that resolutions are announced promptly, including details of the voting results [70][72] Legal Compliance - Any violations of laws or regulations during the meeting can lead to legal challenges within 60 days [27] - The board and relevant parties must execute resolutions promptly and comply with disclosure obligations [27][28]

辽宁成大生物股份有限公司 内部审计制度 第四条 公司董事会审计委员会对内部审计制度的建立健全和有效实施负责，并保 证内部审计相关信息披露内容的真实、准确、完整。 第二章 内部审计机构及人员 第五条 公司董事会设立审计委员会。审计委员会成员为 3 名，为不在公司担任高 级管理人员的董事，其中独立董事 2 名，由独立董事会计专业人士担任召集人。 第六条 公司设置内部审计部门，对公司业务活动、风险管理、内部控制、财务信 息等事项进行监督检查。内部审计部门向审计委员会报告工作。内部审计部门在监督 检查过程中，应当接受审计委员会的监督指导，发现公司重大问题或线索，应当立即 向审计委员会直接报告。 辽宁成大生物股份有限公司 内部审计制度 内部审计部门应当保持独立性，配备专职审计人员，不得置于其他部门的领导之 下，或者与其他部门合署办公。 辽宁成大生物股份有限公司 内部审计制度 第一章 总 则 第一条 为规范辽宁成大生物股份有限公司(以下简称"公司")内部审计工作，加 强公司内部审计监督，防范经营风险，保护投资者的合法权益，根据《中华人民共和 国审计法》《审计署关于内部审计工作的规定》《上海证券交易所科创板上市公司自 律监 ...

Core Points - The document outlines the rules for the board of directors of Liaoning Chengda Biological Co., Ltd, aiming to standardize the decision-making process and enhance the board's operational efficiency [2][3] - The board is required to hold at least two regular meetings annually, with provisions for calling temporary meetings under specific circumstances [4][6] - The rules emphasize the importance of clear communication and documentation, including the necessity for written proposals and meeting notifications [8][10] Group 1 - The board of directors is responsible for making decisions within the scope defined by the company's articles of association and relevant laws [2][3] - The board office handles daily affairs and is responsible for maintaining the board's seal [2] - Proposals for meetings must be submitted in writing, detailing the proposer’s identity and the content of the proposal [6][8] Group 2 - Meetings require the presence of more than half of the directors to be valid, and provisions are made for directors to attend via telecommunication if necessary [11][14] - Directors must personally attend meetings or delegate their voting rights through a written proxy if unable to attend [12][13] - The board must ensure that decisions are made based on thorough discussions and that all relevant factors are considered [8][9] Group 3 - The board is required to review periodic reports carefully, ensuring accuracy and completeness, and must disclose any significant issues [17][20] - Decisions made by the board must receive approval from more than half of the directors present, with specific rules for related party transactions [24][25] - The board is mandated to maintain confidentiality regarding decisions until they are officially disclosed [30][32]

Core Points - Liaoning Chengda Biotechnology Co., Ltd. was established as a joint-stock company in accordance with the Company Law and other relevant regulations [1] - The company completed its initial public offering of 41.65 million shares on October 28, 2021, after approval from the Shanghai Stock Exchange [1][3] - The registered capital of the company is RMB 416.45 million [1] - The company is committed to the research, development, production, and promotion of biological products, adhering to the core values of integrity, responsibility, and quality control [1][2] Company Structure and Governance - The company is governed by a board of directors, with the chairman serving as the legal representative [1] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with its entire assets [1] - The company has established procedures for external guarantees and related party transactions, requiring board or shareholder approval [1][2] Share Issuance and Management - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [3][5] - The total number of shares issued at the time of establishment was 360 million, with the current total being 41.65 million shares [5] - The company has specific regulations regarding the increase, decrease, and repurchase of shares, requiring shareholder approval for significant transactions [5][6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, as well as the right to inspect company documents [9][10] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [25][26] - Shareholders holding more than 3% of shares for over 180 days can request access to the company's accounting records [10] Financial Management and Transactions - The company must submit significant transactions, including guarantees and financial assistance, for shareholder approval [51][52] - Transactions involving related parties that exceed certain thresholds require evaluation and approval [53][54] - The company is prohibited from providing financial assistance for the acquisition of its shares, except under specific conditions [5][6]

Core Points - The document outlines the working rules for the independent director special meetings of Liaoning Chengda Biological Co., Ltd, aiming to enhance corporate governance and protect the interests of minority shareholders and creditors [1][2] - Independent directors are defined as those who do not hold other positions in the company and have no direct or indirect interests that could affect their independent judgment [1][2] - The company is required to hold at least one independent director special meeting annually, with provisions for additional meetings as needed [2][3] Group 1 - The independent director special meeting is convened by a majority of independent directors and requires their presence to proceed [2][3] - Specific matters that must be discussed in these meetings include decisions related to company acquisitions and other significant issues as stipulated by laws and regulations [2][3] - Independent directors have the authority to independently hire intermediaries for audits or consultations and can propose the convening of temporary shareholder meetings [3][4] Group 2 - The meetings must document key discussion points, including related party transactions and any changes to commitments by the company or related parties [4][5] - The company is responsible for providing necessary conditions for the meetings, including operational data and support for independent directors to conduct site visits [5][6] - Confidentiality obligations are imposed on all attending independent directors regarding the matters discussed in the meetings [6]

辽宁成大生物股份有限公司 关联交易管理制度 辽宁成大生物股份有限公司 关联交易管理制度 第一章 总 则 第一条 为进一步加强辽宁成大生物股份有限公司（以下简称"本公司"或 "公司"）的关联交易管理，明确管理职责和分工，维护公司股东和债权人的合 法权益，特别是中小投资者的合法权益，保证公司与关联方之间订立的关联交易 合同符合公平、公开、公正的原则，依据《中华人民共和国公司法》《中华人民 共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）《上海证券交易所上市公司自律监管指引 第5号——交易与关联交易》及其他有关法律、法规规定和《辽宁成大生物股份 有限公司章程》（以下简称"《公司章程》"）的规定，制订本制度。 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本制度。 第三条 公司处理关联交易事项应当遵循下列原则： (一) 符合诚实信用的原则，保证关联交易的合法性、必要性、合理性和公 允性； (二) 公司与关联人之间的关联交易应签订书面协议，协议的签订应遵循平 等、自愿、等价、有偿的原则； (三) 关联董事、关联股东，在就该关联交易相关事项进行表决时，应 ...

Core Viewpoint - The Chinese livestock industry is experiencing a phase of high pig production capacity, prompting the Ministry of Agriculture and Rural Affairs to implement comprehensive production capacity regulation to mitigate risks of price volatility and overproduction [1][2]. Group 1: Market Performance - As of August 12, 2025, the CSI Livestock Breeding Index (930707) increased by 0.68%, with notable gains from companies such as Xiaoming Co. (300967) up 6.50%, Minhe Co. (002234) up 6.19%, and Yisheng Co. (002458) up 3.28% [1]. - The Livestock ETF (159867) rose by 0.46%, marking its third consecutive increase, with the latest price at 0.65 yuan [1]. Group 2: Policy and Regulation - The Ministry of Agriculture and Rural Affairs has announced plans to guide the reduction of approximately 1 million breeding sows to prevent production fluctuations and price instability [1]. - A meeting held on July 23 emphasized strict implementation of production capacity regulation measures, including the rational elimination of breeding sows and control of new production capacity [1]. Group 3: Industry Outlook - Recent policies are expected to accelerate the elimination of inefficient production capacity in the industry, potentially leading to a long-term increase in pig prices, benefiting low-cost and high-quality pig enterprises [1]. - The top ten weighted stocks in the CSI Livestock Breeding Index account for 64.83% of the index, indicating a concentrated market structure [2].

Core Insights - The report highlights the importance of CFOs in listed companies, revealing that the total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] Salary Distribution - The salary distribution shows that the largest proportion of CFOs earn between 500,000 and 1 million yuan, accounting for 31%, followed by those earning between 300,000 and 500,000 yuan at 27%, and those earning between 1 million and 2 million yuan at 21% [5] - Only 4 CFOs earn over 2 million yuan, representing 5% of the total, while 14 CFOs earn between 100,000 and 300,000 yuan, making up 16% [6] Age and Education - The age distribution indicates that the majority of CFOs are between 40 and 50 years old, comprising 43% of the total, while those aged 50 and above account for 42%. CFOs aged 30 to 40 represent only 15% [1] - In terms of education, 48% of CFOs hold a bachelor's degree, 37% have a master's degree, and 16% have an associate degree [3] Salary Changes - Last year, 67% of CFOs saw their salaries increase, with the highest increase recorded by Yang Shaolin from Haida Group, whose salary rose by 2.27 million yuan to 4.26 million yuan [8] - Conversely, 28% of CFOs experienced a salary decrease, with the largest drop seen in Wang Yonghong from Zhengbang Technology, whose salary fell from 2.20 million yuan to 586,000 yuan [8] Industry Insights - In the agriculture, forestry, animal husbandry, and fishery sector, 22 CFOs earned over 1 million yuan, with 5 companies having revenue exceeding 100 billion yuan [6] - Among the pet food companies, CFO salaries are relatively high, with Xiao Mingyan from Zhongchong Co. earning 1.85 million yuan, while the lowest salary in this sector was 197,800 yuan [9]

Summary of Key Points Core Viewpoint - The report highlights the salary trends and demographic characteristics of CFOs in A-share listed companies for 2024, indicating a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan. Group 1: Salary Overview - The total salary of CFOs in A-share listed companies reached 4.27 billion yuan, with an average annual salary of 814,800 yuan [1] - The highest salary recorded was 4.26 million yuan for Yang Shaolin, CFO of Haida Group, with a significant increase of 2.27 million yuan from the previous year [6] - 67% of CFOs experienced salary increases last year, while 28% saw declines [8] Group 2: Industry Breakdown - In the agriculture, forestry, animal husbandry, and fishery sector, the average salary for CFOs was 787,100 yuan, which is below the market average [1] - Among 22 CFOs in the agriculture, forestry, animal husbandry, and fishery sector, 5 had salaries exceeding 1 million yuan [6] - Companies with revenue exceeding 100 billion yuan had CFOs with higher salaries, while smaller companies had lower compensation [6] Group 3: Demographics - The majority of CFOs are aged between 40 and 50 years, accounting for 43% of the total [1] - The educational background shows that 48% of CFOs hold a bachelor's degree, while 37% have a master's degree [3] - The youngest CFO is 32 years old, while the oldest is 63 years old [1] Group 4: Salary Distribution - The most common salary range for CFOs is between 500,000 and 1 million yuan, making up 31% of the total [5] - There are 4 CFOs with salaries exceeding 2 million yuan, representing 5% of the total [5] - The lowest salary recorded was 150,000 yuan for a CFO in the agriculture sector [6]

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]